A phase II study of adjuvant gemcitabine/capecitabine and bevacizumab for patients treated neoadjuvantly chemotherapy for early stage breast cancer with high risk for relapse.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Gemcitabine (Primary)
Indications Adenocarcinoma; Early breast cancer
Focus Adverse reactions

01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
16 Nov 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
16 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com